Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole
Basilea Pharmaceutica Ltd. announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for ceftobiprole by its license partner Janssen-Cilag International NV, a Johnson & Johnson company. This submission is for the use of ceftobiprole in the treatment of complicated skin and soft tissue infections (cSSTI) including diabetic foot infections. according to the company, Ceftobiprole is the first anti-MRSA broad-spectrum cephalosporin antibiotic to complete Phase III clinical trials.
This Marketing Authorization Application (MAA) of ceftobiprole for the treatment of complicated skin and soft tissue infections includes the data from two pivotal phase III trials (STRAUSS 1 and STRAUSS 2). These trials comprise data from over 1600 patients including those with diabetic foot infections caused by Gram-negative, Gram-positive and methicillin-resistant Staphylococcus aureus (MRSA) pathogens. In both multinational, double-blind, randomized phase III studies, ceftobiprole achieved a high clinical cure rate compared to single drug or two-drug combination comparators, respectively. Ceftobiprole was well tolerated with a safety profile consistent with the cephalosporin class of antibiotics.
A milestone payment of approximately CHF 12 million is associated with the MAA filing acceptance.
Ceftobiprole is currently in clinical phase III testing in hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP) and in hospitalized patients with community-acquired pneumonia (CAP) with anticipated completion in the second half of the year.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Researchers shed light on pathway from virus to brain disease

Revealing DNA behavior in record time
Crotalus_pricei
Consortium lead by Prophylix Pharma AS receives up to €6 M in EU-funding - The EU grant is for development of a prophylactic treatment to prevent severe bleeding and death in newborns caused by Fetal/Neonatal Alloimmune Trombocytopenia
The_Knee_Diaries

Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million
Cohesin: a cherry-shaped molecule safeguards cell-division
Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma
Galapagos achieves milestones in strategic alliances with Merck & Co., Inc.
